IVERIC bio, Inc. Common Stock
ISEE
ISEE was delisted on the 10th of July, 2023.
98 hedge funds and large institutions have $1.18B invested in IVERIC bio, Inc. Common Stock in 2014 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 38 increasing their positions, 15 reducing their positions, and 13 closing their positions.
200% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 13
153% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 15
54% more capital invested
Capital invested by funds: $768M → $1.18B (+$412M)
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
34% more funds holding
Funds holding: 73 → 98 (+25)
58% less call options, than puts
Call options by funds: $2.34M | Put options by funds: $5.54M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$68.3M |
| 2 |
JCG
JHL Capital Group
Chicago,
Illinois
|
+$55.8M |
| 3 |
State Street
Boston,
Massachusetts
|
+$13.6M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$12.5M |
| 5 |
Morgan Stanley
New York
|
+$9.24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CV
Clarus Ventures
Cambridge,
Massachusetts
|
-$55M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$44.4M |
| 3 |
CCM
Consonance Capital Management
New York
|
-$11.1M |
| 4 |
ICAP
Independence Capital Asset Partners
Denver,
Colorado
|
-$8.9M |
| 5 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$1.77M |
ISEE Hedge Fund Activity: Q2 2014 in Review
98 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in IVERIC bio, Inc. Common Stock (ISEE) for Q2 2014, worth a combined $1.18B — up 54% from $768M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new ISEE positions and 13 closed out — a net gain of 26 holders — while 38 added to existing stakes and 15 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $68.3M. The largest seller was Clarus Ventures, cutting an estimated $55M.
- 98 institutional investors held IVERIC bio, Inc. Common Stock (ISEE) as of Q2 2014, up from 73 in Q1 2014.
- Funds reported $1.18B of IVERIC bio, Inc. Common Stock stock for Q2 2014, up 54% quarter-over-quarter.
- 39 funds opened new IVERIC bio, Inc. Common Stock positions in Q2 2014 and 13 closed out, a net change of +26 holders.
- The largest IVERIC bio, Inc. Common Stock buyer in Q2 2014 was Fidelity Investments, an estimated $68.3M added.
- The largest IVERIC bio, Inc. Common Stock seller in Q2 2014 was Clarus Ventures, an estimated $55M sold.
Based on aggregated 13F filings for Q2 2014.